Oscar R Durón
@osduvar.bsky.social
Nephrologist. Enthusiast about all things Nephrology. NPATH fellow 2021-2023. NephEdC Internship 2024.
Congratulations to all the Interns of this new program! Looking forward to follow their journey.
June 21, 2025 at 3:08 PM
Congratulations to all the Interns of this new program! Looking forward to follow their journey.
Reposted by Oscar R Durón
Our topic:
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays
the progression of chronic kidney disease (CKD), its effect on patients with autosomal
dominant polycystic kidney dis...
www.kireports.org
March 26, 2025 at 5:42 PM
Our topic:
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
I order it in resistant hypertension or young patients with hypertension. I admit I have a wonderful endocrinologist team who helps me interpret results and go further with more tests if necessary.
February 26, 2025 at 5:19 PM
I order it in resistant hypertension or young patients with hypertension. I admit I have a wonderful endocrinologist team who helps me interpret results and go further with more tests if necessary.
That’s where I am coming from. Thank you for your input on this.
February 20, 2025 at 6:07 PM
That’s where I am coming from. Thank you for your input on this.
Do this interfere on your decision making? Having proteinuria <1 gr or >2 gr can make a difference in some patients.
February 20, 2025 at 5:08 PM
Do this interfere on your decision making? Having proteinuria <1 gr or >2 gr can make a difference in some patients.
That’s a very good point. Thank you.
February 20, 2025 at 7:08 AM
That’s a very good point. Thank you.
Thank you very much. Very helpful! 🙆🏽♂️
February 19, 2025 at 6:46 PM
Thank you very much. Very helpful! 🙆🏽♂️
Now that we are in the subject, do you have any specific use for Cr excretion? Do you consider any specific value for “high” and “low” or just go with what your lab parameters?
February 19, 2025 at 2:58 PM
Now that we are in the subject, do you have any specific use for Cr excretion? Do you consider any specific value for “high” and “low” or just go with what your lab parameters?
I’ll take a look. Thank you very much!
February 19, 2025 at 2:55 PM
I’ll take a look. Thank you very much!
BMI > 30 but no hyperflitration in eGFR.
February 19, 2025 at 2:18 PM
BMI > 30 but no hyperflitration in eGFR.
All I found was this study, which concludes that there is a strong correlation between both tests. In my clinical practice, this is not the case. I want to hear everyone’s thought on this. Here to learn!
www.revistanefrologia.com/es-pdf-X0211...
www.revistanefrologia.com/es-pdf-X0211...
Correlación entre el cociente proteína/creatinina en orina esporádica y las proteínas en orina de 24 horas
www.revistanefrologia.com
February 19, 2025 at 9:15 AM
All I found was this study, which concludes that there is a strong correlation between both tests. In my clinical practice, this is not the case. I want to hear everyone’s thought on this. Here to learn!
www.revistanefrologia.com/es-pdf-X0211...
www.revistanefrologia.com/es-pdf-X0211...
Thank you for the insight @jamiekwillows.bsky.social , it definitely spiced up the discussion. And thank you to all the @nephjc.bsky.social team for having my back on this one. I deeply appreciate it and feel flattered to have the opportunity to participate.
December 17, 2024 at 1:33 PM
Thank you for the insight @jamiekwillows.bsky.social , it definitely spiced up the discussion. And thank you to all the @nephjc.bsky.social team for having my back on this one. I deeply appreciate it and feel flattered to have the opportunity to participate.